Curia's Patented Process For Intermediates Useful For Manufacturing The API Olopatadine HCl

If you're evaluating manufacturing routes for olopatadine hydrochloride (the active pharmaceutical ingredient in Patanol and Pataday), the chemistry matters more than you might expect. Prior art processes, including those described in EP214779, U.S. 5,116,863, and WO2006/010459, share a common set of problems: reliance on hazardous reagents like n-butyl lithium and lithium aluminum hydride, poor Z/E isomer selectivity (typically 2:1 to 2.5:1), and purification demands that require column chromatography or ion exchange resins. None of that scales cleanly.

Curia's scientists identified 6,11-dihydro-11-oxodibenz[b,e]oxepin-2-acetic acid esters and amides as the key intermediates, then built a Wittig reaction pathway around them that prior art had actually dismissed as unworkable. The result, detailed in patent US 9,000,195 B2, achieves Z/E isomer ratios up to 4:1, a meaningful improvement over anything previously described. Dangerous reagents are out. Chromatographic purification is not required. Reagent stoichiometry is tighter. The process is genuinely viable at industrial scale in a way that earlier routes simply weren't.

For manufacturers sourcing or qualifying olopatadine HCl, this is the kind of process chemistry difference that affects yield, cost, and regulatory submission quality. Contact Curia to discuss how this patented process applies to your API manufacturing program.